NCT04995484View on ClinicalTrials.gov

A Study of Belzutifan (MK-6482) in Participants With Hepatic Impairment (MK-6482-020)

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

June 24, 2022

Primary Completion Date

December 25, 2023

Study Completion Date

January 3, 2024

Conditions
Moderate Hepatic Impairment
Interventions
DRUG

Belzutifan

Two 40 mg tablets given as a single oral 80 mg dose.

Trial Locations (2)

32809

Orlando Clinical Research Center ( Site 0001), Orlando

78215

The Texas Liver Institute ( Site 0002), San Antonio

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY